Haleon plc Discloses Share Transaction

TL;DR

Haleon plc bought back its own shares on Oct 1, 2025. Standard 6-K filing.

AI Summary

On October 1, 2025, Haleon plc reported a transaction in its own shares. The filing, a Form 6-K, details this activity as part of its regular reporting for the month of October 2025. This is a standard disclosure for a foreign private issuer.

Why It Matters

This filing indicates corporate actions related to Haleon's own stock, which can provide insights into management's view of the company's valuation or capital allocation strategies.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a share transaction and does not indicate any unusual financial distress or significant operational changes.

Key Players & Entities

• Haleon plc (company) — Registrant
• 01 October 2025 (date) — Date of transaction
• Form 6-K (document) — Filing type

FAQ

Filing Documents

• a5026b.htm (6-K) — 32KB
• a5026b000.jpg (GRAPHIC) — 3KB
• 0001654954-25-011294.txt ( ) — 38KB

From the Filing

IN OWN SHARES a5026b UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of October 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 01 October 2025 - “Transaction in Own Shares”     99.1     Haleon plc:   Transaction in own shares   01 October 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 1,500,000 ordinary shares of £0.01 each in the Company (the "Shares")   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 30 September 2025 30 September 2025 30 September 2025 Number of Shares purchased: 1,500,000 - - Highest price paid per Share (p): 333.3000 - - Lowest price paid per Share (p): 328.4000 - - Volume weighted average price paid per Share (p): 331.3782 - -   The Company intends to hold the purchased shares as treasury shares.   Following the settlement of the above, the Company's registered share capital   is 8,952,353,648 ordinary shares of £0.01 each, of which 44,400,783 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,907,952,865 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/5021B_1-2025-9-30.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zo ë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:  investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .    SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: October 01, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary

View Full Filing

View this 6-K filing on SEC EDGAR